RegularDo-Si-Dos 24/1 avaay 24/1 DID — Hybrid strain with 24% THC / 1% CBD
avaay 24/1 DID · 24% THC / 1% CBD
No ratings recorded yet.
Effects
Review coming soon.
Terpenes
Review coming soon.
Aroma
Review coming soon.
Description
Do-Si-Dos 24/1 offers a sweet and earthy aroma with hints of mint and floral sweetness. The Indica-dominant hybrid has a clearly relaxing, deeply physical effect and is suitable for evenings where rest is needed. Valued for pain, tension, and sleep indications.
Strain Profile: Do-Si-Dos
avaay 24/1 DID is a potent Hybrid strain from the Regular product line by avaay Medical. With a cannabinoid profile of 24% THC and 1% CBD, this batch holds a clear place in the landscape of German medical cannabis strains. Patients with a valid narcotics prescription can find this strain in pharmacies that carry avaay products—availability may vary depending on the region and pharmacy.
Hybrids combine physical and cerebral effects—how these effects are experienced individually depends on the cannabinoid and terpene profile as well as personal condition.
Like any cannabis strain, Do-Si-Dos unfolds its individual effects only through the interplay of cannabinoids, terpenes, and the patient's individual physiology. Prescribing physicians therefore take both the THC/CBD ratio and the specific terpene profile into account when planning treatment.
How to use Do-Si-Dos in everyday life
Time of day & activity: Depending on the phenotype and batch, hybrid strains can be used both during the day and in the evening. Patients therefore often start by testing a small amount in a relaxed setting to assess their personal response.
Typical applications: In medical practice, hybrids cover a broad spectrum: from pain and sleep indications to stress and mood issues. Which characteristics predominate can often be assessed based on the THC/CBD ratio and the terpene profile.
Dosage & titration: The same rule applies to hybrids: start with a low dose, increase slowly, and keep good track of results. Anyone taking other medications simultaneously should discuss potential interactions with their doctor before starting therapy. In addition, our dosage calculator provides an initial reference point for oral applications.
If you are still unsure whether Do-Si-Dos fits your treatment goals, our Product Finder can guide you in three quick steps—based on the area of application, preferred method of consumption, and your prior experience. You can find an overview of all available strains in our strain database.
Information for Patients
Medical cannabis is prescription-only in Germany: obtaining avaay 24/1 DID requires a valid prescription issued by a physician following an individual medical assessment. We explain exactly how to start cannabis therapy in our guide Becoming a Patient as well as in our direct comparison Telemedicine vs. In-Person Doctor.
When choosing a suitable strain, the terpene profile, preferred route of administration, and personal tolerance are just as important as the THC/CBD ratio. For the oral dosage of cannabis extracts or edibles, we offer a dosage calculator as an additional guide—the final dosage should always follow your doctor's instructions.
More about Do-Si-Dos: Use, Science & Origin
Medical Use
Studies & Research
Frequently Asked Questions about Do-Si-Dos
- What is Do-Si-Dos?
- Do-Si-Dos 24/1 features a sweet and earthy aroma with hints of mint and floral sweetness. The Indica-dominant hybrid delivers clearly relaxing, deeply physical effects, making it ideal for restful evenings. It is valued for pain, tension, and sleep issues. Distributed as avaay 24/1 DID.
- What is the THC and CBD content of Do-Si-Dos?
- This batch contains 24% THC and 1% CBD. Other batches or variants may differ.
- Is Do-Si-Dos Indica, Sativa, or a hybrid?
- Do-Si-Dos is classified as a hybrid.
Compare this strain directly
avaay 24/1 DID vs. avaay 20/1 RG & avaay 23/1 CK — THC, CBD, terpenes & effects side by side.
Similar Hybrid strains
View allMore from the HighSpace Universe
Deepen your knowledge of science, legislation, and recipes related to this strain.
Latest News
- Grashaus Projects: How legal cannabis sales work in Switzerland
- CanG 2.0: What changes in 2025 for patients and consumers
- Charité study: CBD more effective for chronic pain than previously thought